Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids

NCT02912468 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02912468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02912468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 5, 2016
Completion date
July 5, 2018
Enrollment
276 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis phenotype with nasal polyps (crswnp)